StreetInsider.com News Articles

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference

Wed, 14 Oct 2026 08:00:00 -0400

SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4^th Annual Immune Cell Engager Virtual Conference being held virtually on October 15, 2026.

H.C. Wainwright 4^th Annual Immune Cell Engager Virtual Conference
Format: Fireside chat
Date: October 15, 2026
Time: 1:30 – 2:00 p.m. ET

A webcast of the fireside

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference

Wed, 14 Oct 2026 08:00:00 -0400

H.C. Wainwright 4^th Annual Immune Cell Engager Virtual Conference
Format: Fireside chat
Date: October 15, 2026
Time: 1:30 – 2:00 p.m. ET

A webcast of the fireside

Form 4 Adagene Inc. For: Sep 30 Filed by: GU CHUNFANG

Fri, 02 Oct 2026 18:05:00 -0400

si-local-file:///var/storage/secattach/20261002/27143836.html

Form 4 Adagene Inc. For: Sep 23 Filed by: Tam Man Kin

Fri, 25 Sep 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260925/27108383.html

Form 6-K Adagene Inc. For: Sep 25

Fri, 25 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260925/27107555.html

Form 6-K Adagene Inc. For: Sep 22

Tue, 22 Sep 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260922/27087886.html

Adagene gets China IND clearance for HER2xCD3 bispecific ADG138

Tue, 22 Sep 2026 08:00:17 -0400

Adagene Inc. (Nasdaq: ADAG) announced that China's National Medical Products Administration (NMPA) has cleared an investigational new drug (IND) application for ADG138, a double-masked HER2×CD3 bispecific T-cell engager. The company expects to begin a Phase 1 clinical study in China in the fourth quarter of 2026.

ADG138 is built on Adagene's SAFEbody precision masking technology, which attaches masking peptides to both the HER2- and CD3-binding arms of the molecule. The drug is designed to remain largely inactive in circulation and become activated within the tumor microenvironment, where it directs T cells to kill HER2-expressing tumor cells.

The planned Phase 1 study is

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Tue, 22 Sep 2026 08:00:00 -0400

Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026

ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective therapy with low systemic toxicity

Preclinical data demonstrated robust tumor regression in tumor models refractory and/or resistant to Enhertu, along with strong synergy in combination with anti-CTLA-4, anti-PD-1 or anti-CD137 antibodies

SAN DIEGO and SUZHOU, China, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”)

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Tue, 22 Sep 2026 08:00:00 -0400

Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026

SAN DIEGO and SUZHOU, China, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”)

Form 4 Adagene Inc. For: Sep 16 Filed by: Luo Peter

Thu, 17 Sep 2026 06:12:00 -0400

si-local-file:///var/storage/secattach/20260917/27072357.html

H.C. Wainwright Reiterates Buy Rating on Adagene Inc (ADAG)

Mon, 14 Sep 2026 07:35:48 -0400

H.C. Wainwright analyst Arthur He reiterated a Buy rating and $7.00 price target on Adagene Inc (NASDAQ: ADAG).

The analyst commented: "On September 9, Adagene announced a $2.0M preclinical milestone payment from Exelixis (EXEL; Buy; Burns) tied to XB404, a SAFEbody-masked antibody-drug conjugate (ADC) directed at ROR1/2-expressing tumors, with a further payment triggered by candidate selection for a second masked ADC program. IND-enabling studies for XB404 are ongoing. On September 10, Third Arc Bio (private) selected the first lead candidate under its amended agreement with Adagene, originally signed in November 2025 covering masked CD3 T cell engagers against unique epitopes of

Third Arc Bio picks lead candidate in amended Adagene collaboration

Thu, 10 Sep 2026 08:03:06 -0400

Adagene Inc. (Nasdaq: ADAG) announced that Third Arc Bio, Inc. has selected its first lead candidate under an amended strategic licensing agreement between the two companies, according to a press release dated Sept. 10, 2026.

The original agreement, established in November 2025, allows Third Arc Bio to use Adagene's NEObody and SAFEbody technology platforms to develop masked CD3 T cell engagers targeting tumor-associated antigens.

Under the amended terms, the collaboration has been broadened. Third Arc Bio will sponsor and fund the clinical development of the selected program. In recognition of the expanded scope, the total potential payments to Adagene, including development and

Third Arc Bio picks lead candidate in amended Adagene collaboration

Thu, 10 Sep 2026 08:03:06 -0400

Form 6-K Adagene Inc. For: Sep 10

Thu, 10 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260910/27045446.html

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Thu, 10 Sep 2026 08:00:00 -0400

Amended terms of agreement include a transition to an integrated asset and technology partnership.

SAN DIEGO and SUZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that Third Arc Bio, Inc. (“Third Arc Bio”) selected the first lead candidate under the amended strategic licensing agreement. The agreement was established in November 2025, under which Third Arc Bio utilizes Adagene’s NEObody® and SAFEbody® technology platform to generate masked CD3 T cell engagers against unique epitopes of

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Thu, 10 Sep 2026 08:00:00 -0400

Amended terms of agreement include a transition to an integrated asset and technology partnership.

Chardan Starts Adagene Inc (ADAG) at Buy

Thu, 10 Sep 2026 06:33:20 -0400

Chardan analyst Gautam Chukka initiates coverage on Adagene Inc (NASDAQ: ADAG) with a Buy rating and a price target of $9.00.

For an analyst ratings summary and ratings history on Adagene Inc click here. For more ratings news on Adagene Inc click here.

Shares of Adagene Inc closed at $3.27 yesterday.

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

Wed, 09 Sep 2026 08:00:00 -0400

SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).

The milestone achievement is related to a preclinical milestone event for XB404 and resulted in a $2.0 million milestone payment from Exelixis. XB404, built with Adagene’s SAFEbody masking technology, is designed to deliver a cytotoxic payload to ROR1/2-expressing tumors while minimizing on-target, off-tumor side effects. An additional

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

Wed, 09 Sep 2026 08:00:00 -0400

Form 144/A Adagene Inc. Filed by: GU CHUNFANG

Thu, 20 Aug 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260820/26957366.html

Form 144/A Adagene Inc. Filed by: GU CHUNFANG

Thu, 20 Aug 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260820/26957366.html

Adagene to Participate in Three Upcoming Investor Conferences

Thu, 20 Aug 2026 08:00:00 -0400

SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in three upcoming investor conferences taking place in New York, New York.

2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026

Format: 1x1 Meetings
Date/Time: September 11, 2026

Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026

Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date/Time: September 15, 2026,

Adagene to Participate in Three Upcoming Investor Conferences

Thu, 20 Aug 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026

Format: 1x1 Meetings
Date/Time: September 11, 2026

Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026

Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date/Time: September 15, 2026,

Adagene to Participate in Three Upcoming Investor Conferences

Thu, 20 Aug 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026

Format: 1x1 Meetings
Date/Time: September 11, 2026

Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026

Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date/Time: September 15, 2026,

Adagene to Participate in Three Upcoming Investor Conferences

Thu, 20 Aug 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026

Format: 1x1 Meetings
Date/Time: September 11, 2026

Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026

Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date/Time: September 15, 2026,